Report Description Table of Contents Industry Report and Statistics (Facts & Figures) - Sales Volume & ASP by Route of Administration & Application The global drug delivery devices market will witness a robust CAGR of 7.1%, valued at $239.2 billion in 2021, expected to appreciate and reach $340.45 billion by 2030, confirms Strategic Market Research. In terms of revenue, North America will account for the maximum industry share in 2020. Providing medication or other pharmacological chemicals to accomplish a therapeutic effect is known as drug delivery. A drug delivery system is a device that provides a drug to the human body for absorption and administration. By managing the rate, time, and location of the ejection of a specific medicine throughout the body, drug delivery systems can offer a therapeutic dose of medication while also increasing safety and efficacy. Physical agents that make up the drug delivery system are known as drug delivery devices. This category encompasses a wide range of devices that people engage in and use daily. Novel drug delivery systems and combinations of products are being developed in modern pharmaceutical companies to meet versatile needs, which includes allowing patients to self-monitor some prescriptions at home, which can help them stick to prescribed regimens. According to the findings of the American Heart Association, cardiovascular disease (CVD) is responsible for roughly 800,000 fatalities in the United States. CVD is responsible for 31 % of all fatalities worldwide. By 2030, the cost of managing CVD is expected to be USD 1,044 billion. Nearly 48 % of women and 46 % of men in the African–American community have some kind of cardiovascular disease. The annual direct and indirect costs are expected to be USD 400 billion. Because of the high costs of pharmaceutical medicines and the need to reduce healthcare spending, novel drug delivery systems can assist in more efficient and accurate drug use. Autoinjectors, Prefilled syringes, metered dose inhalers (MDIs), nasal sprays, nebulizers, transdermal patches, intrauterine devices (iuds), eyedroppers, Infusion pumps, microneedle arrays are some of the drug delivery devices available in the market. These devices are used for medical treatments one or more times. The rising prevalence of acute and chronic illnesses increased R&D spending, and improved government support are the primary drivers of the market. Key Industry Drivers - Increasing Prevalence of Acute & Chronic Illnesses, Nanotechnology and Improved Government Support. The increasing prevalence of acute and chronic illnesses has driven the drug delivery market by increased disease burden, targeted and personalized therapies, improved patient compliance and convenience, advancements in drug delivery technologies, cost-effectiveness and efficiency, regulatory support, and the growing pharmaceutical industry. These factors contribute to the market's expansion as the demand for effective and efficient drug delivery systems rises. Advancements in nanotechnology, biotechnology, and nanocarriers have revolutionized treatment options for these diseases, driving market growth. Regulatory support and market initiatives also encourage investments in research and development of innovative drug-delivery technologies. The growing pharmaceutical industry also drives the focus on research and investment in this sector, further propelling the market's growth. Nanotechnology has become a significant market driver in drug delivery devices, offering numerous advantages and new possibilities for targeted and efficient drug administration. It enables enhanced drug targeting, improved solubility and bioavailability, prolonged and controlled drug release, combination therapies and personalized medicine, and non-invasive administration routes. Nanoparticles can selectively accumulate at the target site, improving drug efficacy and minimizing side effects. This targeted approach enhances therapeutic outcomes and patient compliance, driving the demand for nanotechnology-based drug delivery devices. The global Nanotechnology drug delivery market is growing with a CAGR of 9%, poised to reach $160 Bn by 2030. Nanotechnology also enables the integration of multiple therapeutic agents into a single nanosystem, enabling combination therapies and personalized medicine. Additionally, nanotechnology enables non-invasive administration routes, such as transdermal, nasal, ocular, or buccal administration, improving patient comfort, compliance & safety. Nanoparticle-engineered drugs have been pivotal in treating cancer, HIV-AIDS, and other challenging diseases. Research and development opportunities drive investment in developing and commercializing nanotechnology-based drug delivery devices thus expanding the market. Moreover, the federal government's increased spending is expected to fuel the pace of market growth. According to the Centers for Medicare & Medicaid Services findings, healthcare spending by the federal government increased to 36.0 % in 2020, compared to 5.9 % in 2019. The COVID-19 pandemic was a major factor in this faster growth. In 2020, hospital spending increased by 6.4 % to $1,270.1 billion, faster than the 6.3 % increase in 2019. Furthermore, the healthcare business's expansion and rise, driven by public and private players (e.g., vaccine delivery), will generate lucrative growth prospects, particularly in developing nations. Restraints - Lack of Standardization, Less Number of Professionals, and High Product Cost Lack of standardization, strict approval of drugs, risk of nanoparticles entering the brain, lack of knowledgeable professionals to use some of the devices, and higher cost of technologically advanced devices are restraining the drug delivery devices market growth. Opportunities - Focus on Preventative Treatment, Improved R&D, and Connected Drug Delivery Systems. Increases in personal disposable income, the initiation of technologically driven products in hospitals, increased investment in the development of advanced medical products such as nano-based drug delivery systems, transdermal drug delivery, intracellular delivery (for drug), niosomes, liposomes, microencapsulation, and a rise in the number of cancer cases, respiratory diseases, and diabetic patients in underdeveloped economies all have a positive impact on the growth rate of the industry. The National Council on Aging reported that around 85 % of adults suffer at least one chronic condition. Chronic illnesses are the biggest cause of the nation's healthcare expenses, totaling $3.8 trillion annually. Chronic pain and diabetes are the most expensive chronic illnesses, costing $635 billion and $327 billion annually. Connected drug delivery devices integrate drug delivery systems with digital technologies, such as sensors, wireless connectivity, and data analytics. These devices offer several benefits, including enhanced medication adherence, personalized treatment options, remote patient monitoring, data-driven insights, improved safety and efficiency, and a continuous feedback loop between patients and healthcare providers. The connected drug delivery devices market is projected to reach $26 Bn by 2030, growing with an exponential CAGR of 24%. Medication non-adherence is a significant issue in healthcare, leading to poor treatment outcomes and increased costs. By providing reminders, alerts, and real-time monitoring of medication usage, connected devices ensure that patients take their medications on time and in the correct dosage, improving treatment efficacy and patient outcomes. Personalized treatment options are enabled by collecting & analyzing patient-specific data, allowing healthcare providers to tailor treatment plans to individual patients, improving patient satisfaction, optimizing therapeutic outcomes & reducing the risk of unfavourable events. Remote patient monitoring is particularly beneficial for patients with chronic conditions & those requiring long-term medication. Data-driven insights can drive evidence-based decision-making, proactive patient care & the development of personalized medicine. A continuous feedback loop between patients and healthcare providers is possible, allowing for remote monitoring, timely adjustments to treatment plans, and customized feedback. Overall, connected drug delivery devices represent a significant opportunity for the drug delivery devices market, revolutionizing healthcare delivery by improving patient outcomes, reducing costs, and enhancing patient experiences. Drug Delivery Devices Market Analysis Of Different Segments Covered in the Report The industry segmentation analysis is based on the Route of Administration, Application, End Users, and Region. Based on Route of Administration Ocular Oral Inhalation Topical Injectable Nasal Others Based on Application Cancer Diabetes Cardiovascular Infectious Diseases Others Based on End-user Ambulatory Services Hospitals Home Healthcare Vehicles Outlook (Volume, Units; Revenue, USD Billion, 2016 - 2027) Hydrogel Micelle Dendrimer Nanoparticle Liposome Scaffold Mesoporous Materia Niosomes Regional Coverage Analysis North America The U.S. Canada Europe The U.K. Germany France Asia Pacific China India Japan South Korea Rest of the World Route of Administration Analysis & Insights The drug delivery devices market is categorized into ocular, oral, inhalation, topical, injectable, nasal & others, based on the route of administration. The oral segment dominates the drug delivery devices market with a revenue share of 64.8%, growing with a CAGR of 7.89%, poised to reach $220 Bn by 2030. The oral segment is dominant in the drug delivery devices market due to its convenience, patient compliance, and ease of administration. It offers convenience by eliminating the need for invasive procedures, enhancing patients' independence and quality of life. Patients are more comfortable with oral medications, making them easier to adhere to, especially for chronic conditions. The oral route offers a wide range of formulations, catering to various patient preferences, such as the elderly or pediatric population. The gastrointestinal tract is highly effective in absorbing orally administered drugs, allowing for efficient delivery and sustained release. Oral drug delivery is generally more cost-effective than specialized devices, making it more accessible and affordable for patients. Application Analysis & Insights Based on the application, the drug delivery market applies to cancer, diabetes, cardiovascular, infectious diseases & others. The cancer segment dominates the drug delivery devices market with a revenue share of 47%, poised to reach $160 Bn by 2030. The American Cancer Society estimates US cancer cases and deaths annually, with 1,958,310 new cases and 609,820 deaths projected in 2023. The cancer segment dominates the drug delivery devices market due to its high prevalence, diverse treatment modalities, and the need for localized drug delivery. These devices enable targeted and controlled administration of therapies, enhancing effectiveness and reducing side effects. Drug delivery devices, such as catheters, implantable pumps, and intra-arterial devices, facilitate localized drug delivery, maximizing therapeutic benefits. R&D efforts have focused on developing improved drug delivery devices for cancer treatment, with pharmaceutical companies & medical device manufacturers investing in research & development & commercialization. As the battle against cancer continues, drug-delivery devices remain crucial in improving treatment outcomes & enhancing the quality of life for cancer patients. End Users Analysis & Insights Based on the end-users, the drug delivery devices market is categorized into ambulatory services, hospitals & home healthcare. The hospital segment dominates the drug delivery devices market with a revenue share of 48.9%, poised to reach $166.8 Bn by 2023. The hospital segment dominates the drug delivery devices market due to its advanced medical infrastructure, diverse patient population, specialized treatments, collaborations with pharmaceutical companies, and favourable reimbursement and regulatory environment. These factors include state-of-the-art facilities & a wide range of patient populations, requiring a wide range of drug delivery devices to meet their specific needs. Hospitals also provide inpatient care and monitoring, critical care and life support, and specialized treatments and therapies, requiring specific drug delivery devices for safe and targeted delivery. Hospitals serve as important hubs for these activities, contributing to their dominance in the market. Region Analysis & Insights North America dominates the drug delivery devices market with a revenue share of 39%, growing with a CAGR of 7.67%, poised to reach $132.78 Bn by 2030. North America holds a prominent position in the global drug delivery devices market due to its advanced healthcare infrastructure, robust regulatory frameworks, significant investments in research and development, and large patient population. The region's advanced healthcare infrastructure, strong regulatory frameworks, and large patient population drive the demand for drug-delivery devices. The US and Canada have robust regulatory systems, ensuring medical devices' safety, efficacy, and quality, including drug delivery devices. North America's large patient population, aging population & increasing prevalence of chronic diseases contribute to the growing adoption of drug-delivery devices. Technological advancements in North America enable improved drug administration, personalized treatments, real-time monitoring, and data-driven insights, enhancing patient outcomes and healthcare efficiency. Supportive government policies and collaboration between industry and academia further contribute to North America's dominance in the market. Drug Delivery Devices Market Report Coverage Report Attribute Details Forecast Period 2021 - 2030 The market size value in 2021 USD 239.2 billion The revenue forecast in 2030 USD 340.45 billion Growth rate CAGR of 7.1% The base year for estimation 2021 Historical data 2017 – 2020 Unit USD Billion, CAGR (2021 - 2030) Segmentation By Route of Administration, By Application, By End User, By Region In terms of Route of Administration Ocular, Oral, Inhalation, Nasal, Injectable, Topical, Others In Terms of Application Diabetes, Cancer, Infectious Diseases, Cardiovascular, Others By End-User Ambulatory Services, Home Healthcare, Hospitals. By Region North America, Asia Pacific, Europe, and The Rest of the world Country Scope Canada, Mexico, US, Germany, UK, France, India, Japan, China etc. Company Usability Profiles Pfizer, Inc, Novartis AG, Bayer AG, Shenzhen (SiBiono) , GeneTech Company Ltd.(Hubei Tongji Benda Ebei Pharma), F. Hoffmann-La Roche, 3M, Johnson & Johnson Services, Antares Pharma, Inc, uniQure N.V, Global Drug Delivery Devices Market Competitive Landscape Analysis The existing competitive market analysis gives an overview of some of the key players operating in the global market. Product innovation, Increased investments by venture capitalists, and continued R&D operations to create advanced, sophisticated technologies have assisted the market's growth. In the target market, there are many flourishing companies, and some of the industry leaders are: Bayer AG Becton Dickinson Johnson & Johnson Services Inc Pfizer, Inc Sulzer Ltd. uniQure N.V 3M Novartis AG Shenzhen (SiBiono) F. Hoffmann-La Roche GeneTech Company. Ltd. (Hubei Tongji Benda Ebei Pharma) AstraZeneca PLC GlaxoSmithKline plc Antares Pharma, Inc Medtronic Plc Consort Medical plc (Recipharm Group) Boehringer Ingelheim group Insulet Corporation Industry Recent Developments: On April 2023, Lohmann Therapie-Systeme (LTS) acquired Sorrel's wearable injection device business, adding a large molecule drug delivery platform to its portfolio. Sorrel develops pre-loaded wearable devices for the subcutaneous delivery of large-molecule drugs, including devices with internal drug reservoirs and pre-filled cartridges and vials. LTS's CEO announced that Sorrel's drug delivery platform is ready for a 2023 commercial launch, leveraging LTS's global reach for scalability. The acquisition catapults LTS into the world of drug delivery for large molecules and fulfills LTS's mission to provide empowering solutions for patients relying on expensive therapies. On April 2023, Northwestern University researchers developed a self-powered drug delivery device that can be implanted within the human body. The device uses externally applied light pulses of varying wavelengths to release medication, eliminating the need for surgical removal. The device has three drug reservoirs regulated by a phototransistor and optical filter and three light-emitting diodes (LEDs) with different wavelengths near the implant location. A short circuit triggers electrochemical corrosion, releasing a predetermined medication dosage into the surrounding tissue. The device effectively alleviates pain in rats and can accommodate up to 30 LED wavelengths, allowing for a broader range of pain relief programs. The team evaluates biocompatibility and safety measures before pursuing FDA clearance for human clinical trials. On March 2023, AbbVie received a Complete Response Letter (CRL) from the FDA for its new drug application (NDA) for ABBV-951, a potential treatment for motor fluctuations in adults with advanced Parkinson's disease. The device, a pump, delivers continuous subcutaneous foscarbidopa and foslevodopa over a 24-hour period. AbbVie is committed to bringing this treatment option to those impacted by advanced Parkinson's disease. Compared to oral treatment, the drug candidate has shown statistical superiority in controlling motor fluctuations and improving 'On' time without dyskinesia. The pump-based delivery allows more consistent amounts of levodopa to be delivered to the brain, reducing off times and improving overall effectiveness. On June 2023, Stevanato Group unveiled Vertiva, its patented on-body drug delivery system, designed to switch between basal and bolus injections for various subcutaneous therapies. The device, developed in collaboration with Thermo Fisher Scientific, will be offered as an integrated & fill-and-finish solution. Vertiva features a single-use pod with a pre-filled 3mL ISO cartridge and a multi-use controller for sustainability and affordability. The device can adapt to different delivery profiles and administer small-molecule drugs and biologics. The design is under development for volumes up to 10mL. On May 2023, A new drug delivery system was developed to deliver antioxidants to mitochondria in the liver, mitigating the effects of oxidative stress. Mitochondria is responsible for producing adenosine triphosphate & reactive oxygen species (ROS). Excess ROS damages mitochondria & cells, leading to premature aging and disease. The system was tested in mice models with acetaminophen-induced liver damage and showed that downsized CoQ10-MITO-Porter particles were more effective in treating liver damage than the original formulation. The MITO-Porter system could be used as a therapeutic strategy against conditions causing oxidative stress. On January 2023, Biogen recently established a licensing and collaboration agreement with Alcyone Therapeutics. This agreement aims to develop the ThecaFlex DRx system, a subcutaneous drug delivery system specifically designed to treat neurological disorders such as SMA & ALS. The deal entails payment of $10 Mn to Alcyone as an upfront fee for obtaining an exclusive global license to the system in Spinal Muscular Atrophy (SMA) & Amyotrophic Lateral Sclerosis (ALS). Alcyone holds a co-exclusive international license for a specific indication. The agreement can encompass additional therapies within Biogen's development portfolio. ThecaFlex is a sophisticated medical device specifically engineered to provide targeted delivery of treatments into the cerebrospinal fluid. It comprises an implantable intrathecal catheter, a catheter fixation device, and a subcutaneous port system. The collaboration will primarily concentrate on the clinical development of the system for antisense oligonucleotide (ASO) therapies. Alcyone will assume responsibility for the manufacturing and commercialization of the delivery device. Various Types of Equipment that the Global Market Leaders are Manufacturing: Name Feature Key Player hMTS Easy self-administration of the drug. 3M Unidose Powder System A single-use, ready-to-use one-step nasal administration device is designed to deliver a powder formulation quickly and conveniently in an emergency. Aptar CSP Technologies SYNCHROMED II INTRATHECAL PUMP An implanted catheter administers medicine to the intrathecal area using the SynchroMed II programmable, implantable pump. The Control WorkflowSM technique, which is created to minimize systemic opioids and offer effective pain treatment, can be used to manage SynchroMed II pumps. Medtronic Frequently Asked Question About This Report What are the factors driving the drug delivery devices market? Rising incidence of acute and chronic illnesses, increased R&D spending, and improved government support are the primary drivers of the market. What is the drug delivery devices market growth? It is predicted to reach USD 340.45 billion by 2030, with a CAGR of 4 % throughout the forecasted period. What is the registered CAGR of the drug delivery devices market? Also, mention the CAGR of its sub-segments. The CAGR of the drug delivery devices market is 4 %. Which is the most dominant Region of the Global Drug Delivery Devices Market? In terms of revenue, North America will account for the lions share in 2021 What are some of the global indusrty players? Some major players are Johnson & Johnson Services, Bayer AG, F. Hoffmann-La Roche, 3M, uniQure N.V, Novartis AG, Pfizer, Inc. How big will the Drug Delivery Devices Market be? In 2021, the Global Drug Delivery Devices Market share was USD 239.2 billion and is estimated to reach $340.45 Billion by 2030, representing a CAGR of 7.1% Sources https://professional.heart.org/en/science-news/heart-disease-and-stroke-statistics-2022-update https://www.cdc.gov/tb/worldtbday/history.htm https://www.mckinsey.com/capabilities/strategy-and-corporate-finance/our-insights/securing-europes-competitiveness-addressing-its-technology-gap https://www.cms.gov/newsroom/press-releases/national-health-spending-2020-increases-due-impact-covid-19-pandemic https://www.cancer.org/research/cancer-facts-statistics/global.html https://www.news-medical.net/news/20230510/New-drug-delivery-system-delivers-antioxidant-directly-to-mitochondria-in-the-liver.aspx https://www.massdevice.com/stevanato-group-unveils-drug-delivery-device/ https://physicsworld.com/a/light-triggered-implantable-device-provides-programmable-drug-delivery/ https://www.medicaldevice-network.com/news/lts-large-molecule-drug-delivery-sorrel/ https://pubmed.ncbi.nlm.nih.gov/36633525/ https://www.mdpi.com/1999-4923/15/2/484 https://drug-dev.com/connected-delivery-five-perspectives-on-connected-drug-delivery-devices/ https://en.wikipedia.org/wiki/Nanoparticle_drug_delivery https://www.azonano.com/article.aspx?ArticleID=6435 1. Introduction 1.1. Study Objective 1.2. Market Definition 1.3. Study Scope 1.3.1. Markets Covered 1.3.2. Geographic Scope 1.3.3. Years Considered 1.3.4. Stakeholders 2. Research Methodology 2.1. Data Procurement 2.2. Paid Database 2.2.1. Secondary Data 2.2.1.1. Key Secondary sources 2.2.2. Primary Data 2.2.2.1 Primary sources 2.2.2.2. Key industry insights 2.2.2.3. Primary interviews with experts 2.2.2.4. Key primary respondent list 2.3. Market Size Estimation 2.4. Bottom-Up and Top-Down Approaches 2.4.1. Bottom-Up Approach 2.4.1.1. Approach for arriving at market size by bottom-up analysis 2.4.2. Top-Down Approach 2.4.2.1. Approach for Capturing Market Size by Top-Down Analysis 2.5. Market Breakdown and Data Triangulation 2.6. Research Methodology 2.7. Risk Assessment 3. Executive Summary 3.1 Drug Delivery Devices Market: Post-Covid-19 3.1.1 Actual Scenario 3.1.2 Pessimistic Scenario 3.1.3 Optimistic Scenario 3.1.4 Market Summary 4. Industry Outlook 4.1 Market Snapshot 4.2 Drug Delivery Devices Market 4.2.1 market, 2021 – 2030 (USD Million) 4.3 Regional Business Analysis 4.3.1 market, by region, 2021 - 2030 (USD Million) 4.4 By Route of Administration Business Analysis 4.4.1 market, By Route of Administration, 2021 - 2030 (USD Million) 4.5 By Application Business Analysis 4.5.1 market, By Application, 2021 - 2030 (USD Million) 4.6 Vehicles Business Analysis 4.6.1 market, By Vehicles, 2021 - 2030 (USD Million) 4.6 End-user Business Analysis 4.6.1 market, By End-user, 2021 - 2030 (USD Million) 4.7 Value Chain Analysis 4.8 Market Variable Analysis 4.8.1 Market Drivers Analysis 4.8.2 Market Restraints Analysis 4.9 Business Environment Analysis Tool 4.9.1 market PEST analysis 4.9.2 market Porter’s analysis 4.10 Penetration & Growth Prospect Mapping 5. Market Dynamics 5.1. Introduction 5.2. Market Dynamics 5.2.1. Drivers 5.2.2. Restraints 5.2.3. Opportunities 5.2.4. Challenges 5.3. Impact of Covid-19 On Market 5.4. Value Chain Analysis 5.5. Ecosystem 5.6. Patent Analysis 5.7. Trade Analysis 5.8. Tariff Analysis 5.9. Case Study Analysis 5.10. Porter’s Five Forces Analysis 5.10.1 Threat of New Entrants 5.10.2 Threat of Substitutes 5.10.3 Bargaining Power of Buyers 5.10.4 Bargaining Power of Suppliers 5.10.5 Degree of Competition 5.11. End-user Analysis 5.11.1. Trends in End-user (2014-2021) 5.11.2. Trends in End-user (2021-2030) 5.12. Pricing Analysis 5.12.1. Average Price Trend Analysis (By Region, By Country) 6. Competitive & Vendor Landscape 6.1. Company Market Share Analysis 6.2. Manufacturers Manufacturing Sites, Area Served, Route of Administration 6.3. Market Competitive Situation and Trends 6.4. Manufacturers Mergers & Acquisitions, Expansion Plans 7. Market: By Route of Administration Segment Analysis 7.1. Introduction 7.2. Sales Volume & Revenue Analysis (2021-2030) 7.3. Oral 7.3.1. Oral market, 2021 - 2030 (USD Million) 7.4. Inhalation 7.4.1. Inhalation market, 2021 - 2030 (USD Million) 7.5. Transdermal 7.5.1. Transdermal market, 2021 - 2030 (USD Million) 7.6. Injectable 7.6.1. Injectable market, 2021 - 2030 (USD Million) 7.7. Ocular 7.7.1. Ocular market, 2021 - 2030 (USD Million) 7.8. Nasal 7.8.1. Nasal market, 2021 - 2030 (USD Million) 7.9. Topical 7.9.1. Topical market, 2021 - 2030 (USD Million) 7.10. Others 7.10.1. Others market, 2021 - 2030 (USD Million) 8. Market: By Application Segment Analysis 8.1. Introduction 8.2. Sales Volume & Revenue Analysis (2021-2030) 8.3. Oncology 8.3.1. Oncology market, 2021 - 2030 (USD Million) 8.4. Infectious Diseases 8.4.1. Infectious Diseases market, 2021 - 2030 (USD Million) 8.5. Respiratory Diseases 8.5.1. Respiratory Diseases market, 2021 - 2030 (USD Million) 8.6. Diabetes 8.6.1. Diabetes market, 2021 - 2030 (USD Million) 8.7. Cardiovascular Diseases 8.7.1. Cardiovascular Diseases market, 2021 - 2030 (USD Million) 8.8. Autoimmune Diseases 8.8.1. Autoimmune Diseases market, 2021 - 2030 (USD Million) 8.9. Central Nervous System Disorders 8.9.1. Central Nervous System Disorders market, 2021 - 2030 (USD Million) 8.10. Others 8.10.1. Others market, 2021 - 2030 (USD Million) 9. Market: By Vehicles Segment Analysis 9.1. Introduction 9.2. Sales Volume & Revenue Analysis (2021-2030) 9.3. Hydrogel 9.3.1. Hydrogel market, 2021 - 2030 (USD Million) 9.4. Micelle 9.4.1. Micelle market, 2021 - 2030 (USD Million) 9.5. Dendrimer 9.5.1. Dendrimer market, 2021 - 2030 (USD Million) 9.6. Nanoparticle 9.6.1. Nanoparticle market, 2021 - 2030 (USD Million) 9.7. Liposome 9.7.1. Liposome market, 2021 - 2030 (USD Million) 9.8. Scaffold 9.8.1. Scaffold market, 2021 - 2030 (USD Million) 9.9. Mesoporous Material 9.9.1. Mesoporous Material market, 2021 - 2030 (USD Million) 9.10. Niosomes 9.10.1. Niosomes market, 2021 - 2030 (USD Million) 10. Market: By End-user Segment Analysis 10.1. Introduction 10.2. Sales Volume & Revenue Analysis (2021-2030) 10.3. Hospitals 10.3.1. Hospitals market, 2021 - 2030 (USD Million) 10.4. Diagnostic Centers 10.4.1. Diagnostic Centers market, 2021 - 2030 (USD Million) 10.5. Ambulatory Surgery Centers/Clinics 10.5.1. Ambulatory Surgery Centers/Clinics market, 2021 - 2030 (USD Million) 10.6. Home Care Settings 10.6.1. Home Care Settings market, 2021 - 2030 (USD Million) 10.7. Others 10.7.1. Others market, 2021 - 2030 (USD Million) 11. Market: Regional Outlook 11.1 North America 11.1.1. North America market, By Route of Administration, 2021 - 2030 (USD Million) 11.1.2. North America market, By Application, 2021 - 2030 (USD Million) 11.1.3. North America market, by End-user, 2021 - 2030 (USD Million) 11.1.4. North America market, by Country, 2021 - 2030 (USD Million) 11.1.4.1. U.S. 11.1.4.1.1. U.S. market, By Route of Administration, 2021 - 2030 (USD Million) 11.1.4.1.2. U.S. market, By Application, 2021 - 2030 (USD Million) 11.1.4.1.3. U.S. market, by End-user, 2021 - 2030 (USD Million) 11.1.4.2. Canada 11.1.4.2.1. Canada market, By Route of Administration, 2021 - 2030 (USD Million) 11.1.4.2.2. Canada market, By Application, 2021 - 2030 (USD Million) 11.1.4.2.3. Canada market, by End-user, 2021 - 2030 (USD Million) 11.2. Europe 11.2.1. Europe market, By Route of Administration, 2021 - 2030 (USD Million) 11.2.2. Europe market, By Application, 2021 - 2030 (USD Million) 11.2.3. Europe market, by End-user, 2021 - 2030 (USD Million) 11.2.4. Europe market, by country, 2021 - 2030 (USD Million) 11.2.4.1 U.K. 11.2.4.1.1. U.K. market, By Route of Administration, 2021 - 2030 (USD Million) 11.2.4.1.2. U.K. market, By Application, 2021 - 2030 (USD Million) 11.2.4.1.3. U.K. market, by End-user, 2021 - 2030 (USD Million) 11.2.4.2. Germany 11.2.4.2.1. Germany market, By Route of Administration, 2021 - 2030 (USD Million) 11.2.4.2.2. Germany market, By Application, 2021 - 2030 (USD Million) 11.2.4.2.3. Germany market, by End-user, 2021 - 2030 (USD Million) 11.2.4.3. France 11.2.4.3.1. France market, By Route of Administration, 2021 - 2030 (USD Million) 11.2.4.3.2. France market, By Application, 2021 - 2030 (USD Million) 11.2.4.3.3. France market, by End-user, 2021 - 2030 (USD Million) 11.2.4.4. Rest of Europe 11.2.4.4.1. Rest of Europe market, By Route of Administration, 2021 - 2030 (USD Million) 11.2.4.4.2. Rest of Europe market, By Application, 2021 - 2030 (USD Million) 11.2.4.4.3. Rest of Europe market, by End-user, 2021 - 2030 (USD Million) 11.3. Asia Pacific 11.3.1. Asia Pacific market, By Route of Administration, 2021 - 2030 (USD Million) 11.3.2. Asia Pacific market, By Application, 2021 - 2030 (USD Million) 11.3.3. Asia Pacific market, by End-user, 2021 - 2030 (USD Million) 11.3.4. Asia Pacific market, by country, 2021 - 2030 (USD Million) 11.3.4.1. China 11.3.4.1.1. China market, By Route of Administration, 2021 - 2030 (USD Million) 11.3.4.1.2. China market, By Application, 2021 - 2030 (USD Million) 11.3.4.1.3. China market, by End-user, 2021 - 2030 (USD Million) 11.3.4.2. India 11.3.4.2.1. India market, By Route of Administration, 2021 - 2030 (USD Million) 11.3.4.2.2. India market, By Application, 2021 - 2030 (USD Million) 11.3.4.2.3. India market, by End-user, 2021 - 2030 (USD Million) 11.3.4.3. Japan 11.3.4.3.1. Japan market, By Route of Administration, 2021 - 2030 (USD Million) 11.3.4.3.2. Japan market, By Application, 2021 - 2030 (USD Million) 11.3.4.3.3. Japan market, by End-user, 2021 - 2030 (USD Million) 11.3.4.4. South Korea 11.3.4.4.1. South Korea market, By Route of Administration, 2021 - 2030 (USD Million) 11.3.4.4.2. South Korea market, By Application, 2021 - 2030 (USD Million) 11.3.4.4.3. South Korea market, by End-user, 2021 - 2030 (USD Million) 11.3.4.5. Rest of ASIA PACIFIC 11.3.4.5.1. Rest of ASIA PACIFIC market, By Route of Administration, 2021 - 2030 (USD Million) 11.3.4.5.2. Rest of ASIA PACIFIC market, By Application, 2021 - 2030 (USD Million) 11.3.4.5.3. Rest of ASIA PACIFIC market, by End-user, 2021 - 2030 (USD Million) 11.4. Latin America 11.4.1. Latin America market, By Route of Administration, 2021 - 2030 (USD Million) 11.4.2. Latin America market, By Application, 2021 - 2030 (USD Million) 11.4.3. Latin America market, by End-user, 2021 - 2030 (USD Million) 11.4.4. Latin America market, by country, 2021 - 2030 (USD Million) 11.4.4.1. Brazil 11.4.4.1.1. Brazil market, By Route of Administration, 2021 - 2030 (USD Million) 11.4.4.1.2. Brazil market, By Application, 2021 - 2030 (USD Million) 11.4.4.1.3. Brazil market, by End-user, 2021 - 2030 (USD Million) 11.4.4.2. Mexico 11.4.4.2.1. Mexico market, By Route of Administration, 2021 - 2030 (USD Million) 11.4.4.2.2. Mexico market, By Application, 2021 - 2030 (USD Million) 11.4.4.2.3. Mexico market, by End-user, 2021 - 2030 (USD Million) 11.4.4.3. Rest of the Latin America 11.4.4.3.1. Rest of the Latin America market, By Route of Administration, 2021 - 2030 (USD Million) 11.4.4.3.2. Rest of the Latin America market, By Application, 2021 - 2030 (USD Million) 11.4.4.3.3. Rest of the Latin America market, by End-user, 2021 - 2030 (USD Million) 11.5. MEA 11.5.1. MEA market, By Route of Administration, 2021 - 2030 (USD Million) 11.5.2. MEA market, By Application, 2021 - 2030 (USD Million) 11.5.3. MEA market, by End-user, 2021 - 2030 (USD Million) 11.5.4. MEA market, by Region, 2021 - 2030 (USD Million) 12. Competitive Landscape 12.1 Bayer AG 12.1.1. Company overview 12.1.2. Financial performance 12.1.3. Route of Administration Portfolio Analysis 12.1.4. Business Strategy & Recent Development 12.2. Pfizer, Inc 12.2.1. Company overview 12.2.2. Financial performance 12.2.3. Route of Administration Portfolio Analysis 12.2.4. Business Strategy & Recent Development 12.3. Johnson & Johnson Services, Inc 12.3.1. Company overview 12.3.2. Financial performance 12.3.3. Route of Administration Portfolio Analysis 12.3.4. Business Strategy & Recent Development 12.4. Becton Dickinson 12.4.1. Company overview 12.4.2. Financial performance 12.4.3. Route of Administration Portfolio Analysis 12.4.4. Business Strategy & Recent Development 12.5. F. Hoffmann-La Roche, Ltd 12.5.1. Company overview 12.5.2. Financial performance 12.5.3. Route of Administration Portfolio Analysis 12.5.4. Business Strategy & Recent Development 12.6. Novartis AG 12.6.1. Company overview 12.6.2. Financial performance 12.6.3. Route of Administration Portfolio Analysis 12.6.4. Business Strategy & Recent Development 12.7. 3M 12.7.1. Company overview 12.7.2. Financial performance 12.7.3. Route of Administration Portfolio Analysis 12.7.4. Business Strategy & Recent Development 12.8. UniQure N.V. 12.8.1. Company overview 12.8.2. Financial performance 12.8.3. Route of Administration Portfolio Analysis 12.8.4. Business Strategy & Recent Development 12.9. Shenzhen (SiBiono) 12.9.1. Company overview 12.9.2. Financial performance 12.9.3. Route of Administration Portfolio Analysis 12.9.4. Business Strategy & Recent Development 12.10. Sulzer Ltd 12.10.1. Company overview 12.10.2. Financial performance 12.10.3. Route of Administration Portfolio Analysis 12.10.4. Business Strategy & Recent Development 12.11. GeneTech Co. Ltd 12.11.1. Company overview 12.11.2. Financial performance 12.11.3. Route of Administration Portfolio Analysis 12.11.4. Business Strategy & Recent Development 12.12. Antares Pharma, Inc 12.12.1. Company overview 12.12.2. Financial performance 12.12.3. Route of Administration Portfolio Analysis 12.12.4. Business Strategy & Recent Development 12.13. GlaxoSmithKline plc 12.13.1. Company overview 12.13.2. Financial performance 12.13.3. Route of Administration Portfolio Analysis 12.13.4. Business Strategy & Recent Development 12.14. AstraZeneca PLC 12.14.1. Company overview 12.14.2. Financial performance 12.14.3. Route of Administration Portfolio Analysis 12.14.4. Business Strategy & Recent Development 12.15. Boehringer Ingelheim group 12.15.1. Company overview 12.15.2. Financial performance 12.15.3. Route of Administration Portfolio Analysis 12.15.4. Business Strategy & Recent Development 12.16. Consort Medical plc (Recipharm Group) 12.16.1. Company overview 12.16.2. Financial performance 12.16.3. Route of Administration Portfolio Analysis 12.16.4. Business Strategy & Recent Development 12.17. Insulet Corporation 12.17.1. Company overview 12.17.2. Financial performance 12.17.3. Route of Administration Portfolio Analysis 12.17.4. Business Strategy & Recent Development 12.18. Medtronic Plc 12.18.1. Company overview 12.18.2. Financial performance 12.18.3. Route of Administration Portfolio Analysis 12.18.4. Business Strategy & Recent Development List of Tables (86 Tables) TABLE 1. MARKET, By Route of Administration, 2021-2030 (USD Million) TABLE 2. MARKET FOR Oral, BY REGION, 2021-2030 (USD Million) TABLE 3. MARKET FOR Inhalation, BY REGION, 2021-2030 (USD Million) TABLE 4. MARKET FOR Transdermal, BY REGION, 2021-2030 (USD Million) TABLE 5. MARKET FOR Injectable, BY REGION, 2021-2030 (USD Million) TABLE 6. MARKET FOR Ocular, BY REGION, 2021-2030 (USD Million) TABLE 7. MARKET FOR Nasal, BY REGION, 2021-2030 (USD Million) TABLE 8. MARKET FOR Topical, BY REGION, 2021-2030 (USD Million) TABLE 9. MARKET FOR Others, BY REGION, 2021-2030 (USD Million) TABLE 10. MARKET, By Application, 2021-2030 (USD Million) TABLE 11. MARKET FOR Oncology, BY REGION, 2021-2030 (USD Million) TABLE 12. MARKET FOR Infectious Diseases, BY REGION, 2021-2030 (USD Million) TABLE 13. MARKET FOR Respiratory Diseases, BY REGION, 2021-2030 (USD Million) TABLE 14. MARKET FOR Diabetes, BY REGION, 2021-2030 (USD Million) TABLE 15. MARKET FOR Cardiovascular Diseases, BY REGION, 2021-2030 (USD Million) TABLE 16. MARKET FOR Autoimmune Diseases, BY REGION, 2021-2030 (USD Million) TABLE 17. MARKET FOR Central Nervous System Disorders, BY REGION, 2021-2030 (USD Million) TABLE 18. MARKET FOR Others, BY REGION, 2021-2030 (USD Million) TABLE 19. MARKET, BY END-USER, 2021-2030 (USD Million) TABLE 20. MARKET FOR Hospitals, BY REGION, 2021-2030 (USD Million) TABLE 21. MARKET FOR Diagnostic Centers, BY REGION, 2021-2030 (USD Million) TABLE 22. MARKET FOR Ambulatory Surgery Centers/Clinics, BY REGION, 2021-2030 (USD Million) TABLE 23. MARKET FOR Others, BY REGION, 2021-2030 (USD Million) TABLE 24. MARKET, By Vehicles, 2021-2030 (USD Million) TABLE 25. MARKET FOR Hydrogel, BY REGION, 2021-2030 (USD Million) TABLE 26. MARKET FOR Micelle, BY REGION, 2021-2030 (USD Million) TABLE 27. MARKET FOR Dendrimer, BY REGION, 2021-2030 (USD Million) TABLE 28. MARKET FOR Nanoparticle, BY REGION, 2021-2030 (USD Million) TABLE 29. MARKET FOR Liposome, BY REGION, 2021-2030 (USD Million) TABLE 30. MARKET FOR Scaffold, BY REGION, 2021-2030 (USD Million) TABLE 31. MARKET FOR Mesoporous Material, BY REGION, 2021-2030 (USD Million) TABLE 32. MARKET FOR Niosomes, BY REGION, 2021-2030 (USD Million) TABLE 33. MARKET, BY Home Care Settings, 2021-2030 (USD Million) TABLE 34. MARKET, BY REGION, 2021-2030 (USD Million) TABLE 35. NORTH AMERICA MARKET, BY COUNTRY, 2021-2030 (USD Million) TABLE 36. NORTH AMERICA MARKET, By Route of Administration, 2021-2030 (USD Million) TABLE 37. NORTH AMERICA MARKET, By Application, 2021-2030 (USD Million) TABLE 38. NORTH AMERICA MARKET, BY END-USER, 2021-2030 (USD Million) TABLE 39. EUROPE MARKET, BY COUNTRY, 2021-2030 (USD Million) TABLE 40. EUROPE MARKET, By Route of Administration, 2021-2030 (USD Million) TABLE 41. EUROPE MARKET, By Application, 2021-2030 (USD Million) TABLE 42. EUROPE MARKET, BY END-USER, 2021-2030 (USD Million) TABLE 43. ASIA-PACIFIC MARKET, BY COUNTRY, 2021-2030 (USD Million) TABLE 44. ASIA-PACIFIC MARKET, By Route of Administration, 2021-2030 (USD Million) TABLE 45. ASIA-PACIFIC MARKET, By Application, 2021-2030 (USD Million) TABLE 46. ASIA-PACIFIC MARKET, BY END-USER, 2021-2030 (USD Million) TABLE 47. LAMEA MARKET, BY COUNTRY, 2021-2030 (USD Million) TABLE 48. LAMEA MARKET, By Route of Administration, 2021-2030 (USD Million) TABLE 49. LAMEA MARKET, By Vehicles, 2021-2030 (USD Million) TABLE 50. LAMEA MARKET, BY END-USER, 2021-2030 (USD Million) TABLE 51. Bayer AG: COMPANY SNAPSHOT TABLE 52. Bayer AG: OPERATING SEGMENTS TABLE 53. Pfizer, Inc: COMPANY SNAPSHOT TABLE 54. Pfizer, Inc: OPERATING SEGMENTS TABLE 55. Johnson & Johnson Services, Inc: COMPANY SNAPSHOT TABLE 56. Johnson & Johnson Services, Inc: OPERATING SEGMENTS TABLE 57. Becton Dickinson: COMPANY SNAPSHOT TABLE 58. Becton Dickinson: OPERATING SEGMENTS TABLE 59. F. Hoffmann-La Roche, Ltd: COMPANY SNAPSHOT TABLE 60. F. Hoffmann-La Roche, Ltd: OPERATING SEGMENTS TABLE 61. Novartis AG: COMPANY SNAPSHOT TABLE 62. Novartis AG: OPERATING SEGMENTS TABLE 63. 3M: COMPANY SNAPSHOT TABLE 64. 3M: OPERATING SEGMENTS TABLE 65. UniQure N.V.: COMPANY SNAPSHOT TABLE 66. UniQure N.V.: OPERATING SEGMENTS TABLE 67. Shenzhen (SiBiono): COMPANY SNAPSHOT TABLE 68. Shenzhen (SiBiono): OPERATING SEGMENTS TABLE 69. Sulzer Ltd: COMPANY SNAPSHOT TABLE 70. Sulzer Ltd: OPERATING SEGMENTS TABLE 71. GeneTech Co. Ltd: COMPANY SNAPSHOT TABLE 72. GeneTech Co. Ltd: OPERATING SEGMENTS TABLE 73. Antares Pharma, Inc: COMPANY SNAPSHOT TABLE 74. Antares Pharma, Inc: OPERATING SEGMENTS TABLE 75. GlaxoSmithKline plc: COMPANY SNAPSHOT TABLE 76. GlaxoSmithKline plc: OPERATING SEGMENTS TABLE 77. AstraZeneca PLC: COMPANY SNAPSHOT TABLE 78. AstraZeneca PLC: OPERATING SEGMENTS TABLE 79. Boehringer Ingelheim group: COMPANY SNAPSHOT TABLE 80. Boehringer Ingelheim group: OPERATING SEGMENTS TABLE 81. Consort Medical plc (Recipharm Group): COMPANY SNAPSHOT TABLE 82. Consort Medical plc (Recipharm Group): OPERATING SEGMENTS TABLE 83. Insulet Corporation: COMPANY SNAPSHOT TABLE 84. Insulet Corporation: OPERATING SEGMENTS TABLE 85. Medtronic Plc: COMPANY SNAPSHOT TABLE 86. Medtronic Plc: OPERATING SEGMENTS List of Figures (24 Figures) Figure 1 Market: Research Methodology Steps Figure 2 Research Design Figure 3 Breakdown of Primaries: Market Figure 4 Research Methodology: Hypothesis Building Figure 5 Market: Route of Administration-Based Estimation Figure 6 Top 18 Companies with Highest No. Of Patent in Last 9 Years Figure 7 No. Of Patents Granted Per Year, 2019–2021 Figure 8 Import Data for Drug Delivery Devices Market, By Country, 2016–2021 (USD Thousand) Figure 9 Export Data for Drug Delivery Devices Market, By Country, 2016–2021 (USD Thousand) Figure 10 Data Triangulation Methodology Figure 11 Market, By Application, 2019 vs. 2025 (USD Million) Figure 12 Market Share, By End-user, 2019 vs. 2025 (USD Million) Figure 13 Market Share, By Route of Administration, 2019 vs. 2025 (USD Million) Figure 14 Market Share, By Vehicles, 2019 vs. 2025 (USD Million) Figure 15 Geographical Snapshot of the Market Figure 16 Oral to Witness Higher CAGR in Market for Route of Administration Segment during Forecast Period. Figure 17 Hospitals to Witness Higher CAGR in Market for End-user Segment during Forecast Period. Figure 18 Cancer to Witness Higher CAGR in the Market for Application Segment during Forecast Period. Figure 20 North America Accounted for the Largest Share of the Market, By Regional Basis, in 2019 Figure 21 Market: Drivers, Restraints, Opportunities, and Challenges Figure 22 North America: Market Snapshot Figure 23 Asia Pacific: Market Snapshot Figure 24 Vendor Dive: Evaluation Overview